Robert James Wills
Robert James Wills's purchase track record
Robert James Wills has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/21/2026 | ACOG | $96K | pending | pending | — |
| 8/18/2025 | ACOG | $127K | -30.1% | -38.3% | +6.1% |
| 10/19/2022 | MIST | $74K | -23.6% | -22.8% | +12.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Milestone Enrolls First Canadian Participant in Phase 3 AFib Trial. Milestone Pharmaceuticals reported that the first Canadian participant has been enrolled in its ReVeRA‑301 Phase 3 trial of the epiripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks a key step toward the pivotal study that will evaluate the drug’s efficacy and safety in a larger population. The company’s progress in this trial could influence future regulatory decisions and market perception of the product.
Transaction History
| ACOG | ▲ Buy | Open Market | 10,000 | $96K | 8/21/2026 | View on chart |
| ACOG | ▲ Buy | Grant | 7,241 | $0 | 1/14/2026 | View on chart |
| ACOG | ▲ Buy | Open Market | 15,000 | $127K | 8/18/2025 | View on chart |
| MIST | ▲ Buy | Grant | 50,000 | — | 7/11/2025 | View on chart |
| MIST | ▲ Buy | Open Market | 15,000 | $74K | 10/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Alpha Cognition Releases 180-Day Data on CONVERGE Program
Alpha Cognition has published results from a 180‑day study of its CONVERGE program. The data covers patients who are taking ZUNVEYL, donepezil, galantamine or rivastigmine. The release gives a clearer view of how the program performs in real‑world use. Investors can use the information to assess the company’s therapeutic strategy.
Alpha Cognition Releases 180-Day Data on CONVERGE Program. Alpha Cognition has published results from a 180‑day study of its CONVERGE program. The data covers patients who are taking ZUNVEYL, donepezil, galantamine or rivastigmine. The release gives a clearer view of how the program performs in real‑world use. Investors can use the information to assess the company’s therapeutic strategy.